tiprankstipranks
Molecular Partners AG (CH:MOLN)
:MOLN
Switzerland Market
MOLN
Molecular Partners AG
RESEARCH TOOLSreports
Want to see CH:MOLN full AI Analyst Report?

Molecular Partners AG (MOLN) Stock News & Sentiment

0 Followers
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
Premium
Ratings
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
6d ago
MOLN
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
Premium
Ratings
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
27d ago
MOLN
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
Premium
Ratings
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
2M ago
MOLN
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
Premium
Ratings
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
2M ago
MOLN
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
Premium
Ratings
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
2M ago
MOLN
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
Premium
Ratings
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
3M ago
MOLN
Molecular Partners Advances DLL3 Radioligand Program With New Phase 1/2a Cancer Trial
Premium
Company Announcements
Molecular Partners Advances DLL3 Radioligand Program With New Phase 1/2a Cancer Trial
4M ago
MLLCF
More CH:MOLN News >

MOLN News on the Web

Molecular Partners announces presentation of preclinical data at AACR
TipRanks News
Bullish
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
TipRanks News
Bullish
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
TipRanks News
Bullish
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
TipRanks News
Bullish
Molecular Partners (MOLN) Gets a Buy from Clear Street
TipRanks News
Bullish
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
TipRanks News
Bullish
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
TipRanks News
Bullish
Molecular Partners AG conference call and Webcast Transcript
GuruFocus News
Neutral

News Score - Last 7 Days

Very Positive
CH:MOLN
Sector Average
Media Buzz
This Week1 articles
Weekly Average0.75 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:MOLN’s Media Buzz Sentiment?
1 articles about CH:MOLN were published this week. In an average week, 0.75 articles are published.
    What is CH:MOLN’s weekly average amount of articles?
    In an average week, 0.75 articles about CH:MOLN are published.
      What is CH:MOLN’s News Sentiment?
      100% of articles about CH:MOLN were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week